Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma.
Expert Opin Biol Ther
; 24(5): 339-350, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38738379
ABSTRACT
INTRODUCTION:
Ciltacabtagene autoleucel (cilta-cel), a BCMA-targeting CAR-T therapy, is approved in the United States and Europe for patients with relapsed/refractory multiple myeloma (RRMM) and ≥1 prior line of therapy (LOT), including a proteasome inhibitor and an immunomodulatory drug, and are lenalidomide refractory. AREAS COVERED We examine recent long-term data in heavily pretreated RRMM (LEGEND-2, CARTITUDE-1) and earlier LOTs (CARTITUDE-4) compared with standard therapy and discuss the rationale for investigating cilta-cel as frontline therapy for transplant-eligible and transplant-ineligible patients (CARTITUDE-5, CARTITUDE-6). EXPERT OPINION CAR-T therapies can improve outcomes for patients with MM across different LOTs. CARTITUDE-1 and CARTITUDE-4 have set a new bar for efficacy, with median PFS of 34.9 months in heavily pretreated patients (CARTITUDE-1) and a 74% relative risk reduction for progression/death versus standard care in patients with 1-3 prior LOTs (CARTITUDE-4), with manageable safety. Response rates were consistent between the two studies 98% in CARTITUDE-1 and approaching 100% for infused patients in CARTITUDE-4. Cilta-cel could be a key treatment choice for patients with RRMM after first LOT. Clinical trials investigating frontline cilta-cel therapy will provide valuable insights into optimizing treatment pathways with the aim to potentially cure MM.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Inmunoterapia Adoptiva
/
Antígeno de Maduración de Linfocitos B
/
Mieloma Múltiple
Límite:
Humans
Idioma:
En
Revista:
Expert Opin Biol Ther
/
Expert opin. biol. ther. (Online)
/
Expert opinion on biological therapy (Online)
Asunto de la revista:
BIOLOGIA
/
TERAPEUTICA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos